SAN DIEGO, Sept. 14 /PRNewswire/ -- aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the BioPharm America 2009 conference in San Francisco, CA on Friday, September 18th. Jeff Watkins, CEO of aTyr Pharma, will present an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.
According to Cheryl Quinn, Director of Business Development at aTyr Pharma, "Because our product engine is based on the emerging new science of resectin proteins, we look forward to introducing aTyr Pharma's exciting new science and portfolio to the attendees of BioPharma America."
About aTyr Pharma
aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.
|SOURCE aTyr Pharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved